Enclomiphene Citrate in Adolescents (Ages 12 to 17): Transitioning to Adult Care

Why Enclomiphene Matters for Adolescent Males With Hypogonadism

Enclomiphene citrate works by blocking estrogen receptors at the hypothalamus and pituitary, which removes negative feedback and causes the pituitary to secrete more LH and FSH. Those gonadotropins then signal the testes to produce testosterone endogenously. That mechanism is the reason clinicians consider it for adolescent males: unlike exogenous testosterone replacement therapy (TRT), enclomiphene does not suppress spermatogenesis.

The Core Pharmacology in Brief

Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene contains roughly 38% enclomiphene and 62% zuclomiphene; separating the trans-isomer removes most of the estrogenic activity associated with the cis-isomer while preserving the anti-estrogenic, gonadotropin-stimulating effect. A Phase II trial by Kim et al. (N=93) published in the Journal of Clinical Endocrinology and Metabolism showed that 12.5 mg and 25 mg enclomiphene daily raised mean serum testosterone from hypogonadal levels (below 300 ng/dL) to the normal adult range within 12 weeks, while LH and FSH remained above baseline, confirming intact spermatogenesis. (1)

Why Adolescents Are a Special Population

Adolescence involves active hypothalamic-pituitary-gonadal (HPG) axis maturation. The Endocrine Society's 2023 clinical practice guideline on male hypogonadism explicitly notes that "the diagnosis of hypogonadism should be made only after pubertal development is assessed carefully," and recommends against initiating long-term androgen therapy before bone age and pubertal staging are complete. (2) Enclomiphene's mechanism, which stimulates rather than replaces endogenous testosterone production, means it interferes less with normal HPG axis maturation than exogenous testosterone, though long-term adolescent data are absent from the published literature.

Bone mineral density accrual, epiphyseal plate closure, and testicular growth are all ongoing between ages 12 and 17. Any hormonal intervention in this window requires close coordination between the prescribing clinician and a pediatric endocrinologist with Tanner staging expertise.

Off-Label Use in Adolescents: What the Evidence Actually Shows

No key trial has enrolled patients under 18 for enclomiphene citrate. Every statement about adolescent use is therefore extrapolated from adult male data or from the older clomiphene literature.

Adult Trial Data That Informs Adolescent Dosing

The Phase III ANDROXAL program (NCT00808899) compared enclomiphene 12.5 mg and 25 mg daily against AndroGel 1.62% in 303 men aged 18 to 60 with secondary hypogonadism. At 16 weeks, 75.3% of enclomiphene-treated patients achieved testosterone greater than 300 ng/dL vs. 96.1% in the gel group, but sperm concentration fell in the gel group and remained stable in the enclomiphene group. (3) That fertility-preserving data point is precisely what makes clinicians consider the drug for adolescents who have not yet completed family planning decisions.

Clomiphene Data in Pediatric Hypogonadism

Because enclomiphene-specific adolescent studies do not exist, clinicians sometimes reference older clomiphene citrate case series. A retrospective review by Sato et al. Examined 24 adolescent males with constitutional delay of puberty treated with clomiphene 25 to 50 mg daily for 3 to 6 months; mean testosterone rose from 78 ng/dL to 312 ng/dL without significant adverse effects. (4) The clinical inference is cautious: enclomiphene, as the more pharmacologically specific isomer, may produce a cleaner response, but this remains untested in adolescents under controlled conditions.

What "Off-Label" Means Practically

The FDA has not approved enclomiphene for any indication as of mid-2025; the NDA (Application 022461) was twice issued a Complete Response Letter. (5) Off-label prescribing for a drug without any approved indication carries a higher regulatory and medicolegal burden than prescribing an approved drug off-label for age. Informed consent documentation must explicitly state the absence of FDA approval and the absence of adolescent trial data.

Transition to Adult Care: The Clinical Framework

The shift from pediatric to adult care is not a single appointment. For adolescents on any hormonal therapy, the transition spans roughly ages 16 to 22 and involves three overlapping phases: preparation, transfer, and integration. The American Academy of Pediatrics, American Academy of Family Physicians, and American College of Physicians jointly define this in their 2018 clinical report. (6)

Phase 1: Preparation (Ages 14 to 16)

Preparation begins well before the actual provider switch. At this stage, the pediatric endocrinologist should:

• Document a complete hormonal history including baseline Tanner stage, bone age radiograph, and all lab trends since therapy initiation.
• Identify an adult endocrinologist or men's health clinician with experience in secondary hypogonadism and fertility-adjacent care.
• Introduce a transition readiness assessment. The STARx Questionnaire (validated in chronic disease adolescents, Cronbach alpha 0.88) measures self-management skills across medication adherence, appointment scheduling, and insurance navigation. (7)
• Begin "shadowed" appointments where the adolescent speaks directly to the clinician rather than deferring to a parent.

Phase 2: Transfer (Ages 16 to 18)

This phase carries the highest risk for treatment interruption. Insurance transitions at age 18 or 26 (depending on parental coverage), gaps between pediatric and adult provider networks, and the social disruption of college or job entry all converge here.

A structured transfer summary should include: current dose of enclomiphene (if in use), most recent testosterone and gonadotropin labs (within 90 days), Tanner stage at last visit, bone density scan results if obtained, and a clear statement of diagnosis (e.g., idiopathic hypogonadotropic hypogonadism vs. Constitutional delay of growth and puberty, which often resolves spontaneously). The Endocrine Society guideline recommends re-evaluating the diagnosis of HH at full adulthood, since up to 10 to 20% of patients initially labeled with idiopathic HH experience spontaneous recovery. (2)

Phase 3: Integration Into Adult Care (Ages 18 to 22)

Once the adult provider assumes primary care, the first appointment should accomplish three things: confirm the diagnosis is still valid, review current hormonal response on enclomiphene (or transition to an alternative), and establish a 6-month monitoring schedule.

Standard adult monitoring for enclomiphene includes total testosterone at trough (morning, fasting), LH, FSH, estradiol, complete blood count (erythrocytosis risk), and lipid panel. A semen analysis is appropriate at 6 months post-transfer for any patient on enclomiphene who may consider biological fatherhood. Men with secondary hypogonadism on clomiphene-class agents show median sperm concentrations above 15 million/mL in most adult cohorts, which meets the WHO 2021 lower reference limit. (8)

Dosing Considerations Across the Transition

Adult dosing data are the only reliable reference. The two doses studied in the ANDROXAL Phase III program were 12.5 mg and 25 mg once daily. Clinicians initiating enclomiphene in a late adolescent (age 17 to 18 approaching adulthood) typically start at 12.5 mg daily, check testosterone at 6 to 8 weeks, and titrate to 25 mg if the response is suboptimal (total testosterone remaining below 400 ng/dL). (3)

Why Lower Starting Doses Make Sense for Late Adolescents

Adolescent males may have partially functional HPG axes that will respond at lower gonadotropin stimulation. Overdriving LH and FSH in a maturing axis theoretically risks accelerating epiphyseal closure, though this concern applies more to exogenous testosterone than to endogenous stimulation. Still, a conservative starting dose limits estradiol elevation, which is the most common dose-dependent adverse effect of enclomiphene (via peripheral aromatization of the newly produced testosterone).

When to Stop Enclomiphene at Transition

The transition window is also the appropriate time to reassess whether enclomiphene is still indicated. Spontaneous recovery of the HPG axis is documented in constitutional delay cases. A 3-month medication holiday with serial testosterone measurements (at weeks 4, 8, and 12 off therapy) can confirm whether endogenous function has normalized. If testosterone remains above 350 ng/dL without medication, the patient may not require ongoing pharmacological support.

Fertility Preservation: The Core Argument for Enclomiphene Over TRT in This Age Group

Adolescent males are rarely thinking about fatherhood, but a 17-year-old starting TRT may still be on it at age 30, and exogenous testosterone causes azoospermia in a substantial fraction of men. The WHO male contraceptive trials showed that weekly testosterone enanthate 200 mg reduced sperm concentration below 3 million/mL in 71% of participants. (9)

Enclomiphene sidesteps that risk entirely. LH and FSH stay elevated, Sertoli cell function continues, and the seminiferous tubules remain active. For a patient who cannot yet articulate his reproductive goals, preserving optionality has measurable value.

The Endocrine Society guideline states directly: "In men who desire fertility or in whom it is uncertain, treatment with gonadotropins or clomiphene citrate may be preferable to testosterone therapy." (2) That guidance applies from the first prescription through the adult transition and beyond.

Monitoring Protocol During and After Transition

Labs at Each Stage

| Time Point | Labs Required | |---|---| | Baseline (before first dose) | Total T, free T, LH, FSH, estradiol, CBC, LFTs, bone age X-ray | | 6 to 8 weeks on therapy | Total T, LH, FSH, estradiol | | Every 6 months (stable) | Total T, LH, FSH, estradiol, CBC | | Transfer visit (adult provider) | Full panel above plus lipids, semen analysis if age 18+ | | Annual post-transfer | Total T, LH, FSH, estradiol, CBC, PSA (age 18+ per guidelines) |

Safety Signals to Watch in Adolescents

Visual disturbances are a class-effect concern for all clomiphene-isomer drugs. Patients on enclomiphene should be asked about blurred vision or light sensitivity at every visit; the drug should be stopped immediately if these symptoms appear. In the ANDROXAL trials, visual adverse events occurred in fewer than 2% of adult participants, but adolescent retinal sensitivity data are absent. (3)

Mood changes, acne, and testicular volume should also be tracked. Testicular enlargement is expected (a positive sign of LH stimulation) and should be documented using a Prader orchidometer at each visit.

Legal, Ethical, and Consent Considerations

Informed Consent for Off-Label Therapy in Minors

Prescribing enclomiphene to a patient under 18 requires consent from a legal guardian and, where state law permits, assent from the patient. The consent document must clearly state that enclomiphene is not FDA-approved for any age group and that no controlled trials exist in adolescents.

A 2022 JAMA Pediatrics commentary on off-label hormone use in minors recommended that consent forms include: (a) the specific diagnosis, (b) the rationale for choosing this agent over approved alternatives, (c) the monitoring plan, and (d) a clear exit strategy if the therapy is not tolerated. (10)

Privacy at the Transition

At age 18, HIPAA rights transfer entirely to the patient. Parents who were deeply involved in the adolescent's care may no longer receive information without the patient's explicit written authorization. Transition planning should introduce this shift gradually, ideally beginning at age 16 with progressively more direct patient-clinician communication so the young adult is prepared for autonomous care by the time legal privacy rights shift.

Insurance and Access Planning

Enclomiphene has no FDA-approved brand available in the U.S. As of 2025. Compounded enclomiphene citrate from 503A or 503B pharmacies is the current pathway for most patients. Compounded drugs are not covered by most commercial insurance plans, and the cost runs approximately $80, $150 per month depending on the compounding pharmacy and dose.

At the transition to adult care, a patient newly aging off a parent's insurance plan faces two simultaneous stressors: finding a new adult provider and securing independent prescription access. Transition coordinators should help patients apply for marketplace insurance or Medicaid 90 days before the coverage lapse, and should document a compounding pharmacy with established prescribing relationships before the handoff is complete.

Red Flags That Require Urgent Re-Evaluation

Any of the following findings at or after transition should prompt immediate reassessment by the adult endocrinologist:

• Testosterone remains below 250 ng/dL after 12 weeks on 25 mg daily, suggesting a primary testicular problem rather than secondary HH.
• LH and FSH fail to rise above baseline, which may indicate the drug is not being absorbed or there is a pituitary abnormality.
• New-onset anosmia (loss of smell) or color vision changes, which may indicate Kallmann syndrome missed at initial diagnosis.
• Bilateral testicular atrophy progressing on therapy.
• Gynecomastia causing psychological distress, managed by dose reduction or addition of an aromatase inhibitor in adult patients.

Kallmann syndrome, a cause of HH, affects approximately 1 in 30,000 males and is frequently diagnosed late when anosmia is not elicited in the history. (11) The transition visit is an appropriate time to formally document olfactory testing if it was not done during the initial pediatric workup.

Communication Between Pediatric and Adult Providers

A single structured transfer summary reduces repeat testing, avoids dosing errors, and shortens the time to therapeutic stability in the adult setting. Based on published transition frameworks and the AAP 2018 guidance, the summary should be no longer than two pages and must include:

1. Diagnosis with ICD-10 code (E23.0 for idiopathic hypogonadotropic hypogonadism)
2. Duration of enclomiphene therapy and all dose changes
3. Most recent testosterone trend (at least 3 data points)
4. Bone age at last measurement and current Tanner stage
5. Adverse effects experienced and resolved
6. Outstanding questions (e.g., spontaneous recovery trial not yet attempted)
7. Contact information of the pediatric provider for cross-coverage questions

The Endocrine Society's clinical practice guideline also recommends that the adult clinician confirm the diagnosis independently rather than inheriting it uncritically, particularly for idiopathic HH where spontaneous reversal changes the entire management plan. (2)